benefits of glp-1 agonists In patients with #obesity, incretin-based

[DOI] [PubMed] [Google Scholar] 15.Bansal R., Khan R.J., Grover S.C

Although currently FDA-approved for diabetes and weight management, clinical evidence indicates these medications also interact with the brains neurological reward pathways involved in substance use disorder

In conclusion, incretins and GLP-1 analogs by suppressing macrophage cell formation prevent the development of atherosclerotic lesions

At this time, GLP-1/GIP medications should not be represented as disease-modifying therapy for autoimmune disorders

While type 1 often manifests as an autoimmune insulin deficiency during childhood, T2DM predominantly develops throughout life

Weeks 1 through 4: the initial adjustment The first month on retatrutide after tirzepatide feels like starting over